Trastuzumab Deruxtecan Approved in Japan for HER2-Mutated Metastatic NSCLC
Japan’s Ministry of Health, Labour, and Welfare has approved fam-trastuzumab deruxtecan-nxki for use in adult patients with unresectable advanced or recurrent, HER2-mutant non–small cell lung cancer that has progressed following chemotherapy.
Source: onclive.com